How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

741 results for

Impetigo

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Impetigo: antimicrobial prescribing

Impetigo: antimicrobial prescribing Impetigo: antimicrobial prescribing NICE guideline Published: 26 February 2020 www.nice.org.uk/guidance/ng153 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals (...) and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Impetigo: antimicrobial prescribing (NG153) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 28Contents Contents Overview 4 Who is it for? 4 Recommendations 5 1.1 Managing impetigo 5 1.2 Choice of antimicrobial 8

2020 National Institute for Health and Clinical Excellence - Clinical Guidelines

2. Impetigo

Impetigo Impetigo - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Impetigo Last reviewed: February 2019 Last updated: January 2018 Summary Highly contagious and common bacterial infection of the skin that typically occurs in children; a key consideration for schools and playgroups. Typically staphylococcal or streptococcal. Diagnosis is usually clinical, bacterial skin cultures are reserved for extensive disease (...) ), or if deeper infection is suspected. Definition Impetigo is a superficial, contagious, blistering infection of the skin caused by the bacteria Staphylococcus aureus and Streptococcus pyogenes . It hastwo forms: non-bullous and bullous. Bullae are fluid-filled lesions of >0.5 cm in diameter. Non-bullous impetigo is the more common form (accounting for 70%). Hartman-Adams H, Banvard C, Juckett G. Impetigo: diagnosis and treatment. Am Fam Physician. 2014;90:229-235. http://www.aafp.org/afp/2014/0815/p229.html

2018 BMJ Best Practice

3. Topical Antibiotics for the Treatment of Treatment-Resistant Impetigo: Clinical Effectiveness and Guidelines

Topical Antibiotics for the Treatment of Treatment-Resistant Impetigo: Clinical Effectiveness and Guidelines Topical Antibiotics for the Treatment of Treatment-Resistant Impetigo: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Topical Antibiotics for the Treatment of Treatment-Resistant Impetigo: Clinical Effectiveness and Guidelines Topical Antibiotics for the Treatment of Treatment-Resistant Impetigo: Clinical Effectiveness and Guidelines Last updated: October (...) 4, 2018 Project Number: RA0968-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical evidence regarding the use of topical antibiotics for the treatment of treatment-resistant impetigo? What are the evidence-based guidelines regarding the treatment of treatment resistant impetigo? Key Message One systematic review with meta-analyses, one non-randomized study, and one evidence-based guideline were identified regarding the clinical

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

4. Ozenoxacin (Xepi) - To treat impetigo

Ozenoxacin (Xepi) - To treat impetigo Xepi (ozenoxacin) Cream U.S. Department of Health and Human Services Search FDA Submit search Xepi (ozenoxacin) Cream Xepi Company: Ferrer Internacional S.A. Application No.: 208945 Approval Date: 12/11/2017 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: January 18, 2018 Vision impaired

2018 FDA - Drug Approval Package

6. Ozanex - ozenoxacin - Impetigo

Ozanex - ozenoxacin - Impetigo ozenoxacin | CADTH.ca Find the information you need ozenoxacin ozenoxacin Last Updated: November 27, 2018 Result type: Reports Project Number: SR0553-000 Product Line: Generic Name: ozenoxacin Brand Name: Ozanex Manufacturer: Ferrer Internacional, S.A. Indications: Impetigo Manufacturer Requested Reimbursement Criteria 1 : For the topical treatment of impetigo in patients aged 2 months and older. Submission Type: New Project Status: Complete Biosimilar (...) request granted - Reconsideration requested Applicant's request for reconsideration placed on CDEC agenda October 17, 2018 CDEC Final Recommendation issued to applicant and drug plans October 24, 2018 CDEC Final Recommendation posted October 26, 2018 Final CDR review report(s) and patient input posted October 29, 2018 Tags dermatology, pediatrics, impetigo, Ozanex; ozenoxacin; Xepi; impetigo; Pediatric; Paediatric; Child Files Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get

2018 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

7. Topical Antibiotics for Impetigo: A Review of the Clinical Effectiveness and Guidelines

Topical Antibiotics for Impetigo: A Review of the Clinical Effectiveness and Guidelines Topical Antibiotics for Impetigo: A Review of the Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Topical Antibiotics for Impetigo: A Review of the Clinical Effectiveness and Guidelines Topical Antibiotics for Impetigo: A Review of the Clinical Effectiveness and Guidelines Published on: February 21, 2017 Project Number: RC0851-000 Product Line: Research Type: Drug Report Type (...) : Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of topical antibiotics for patients with impetigo? What are the evidence-based guidelines regarding the use of topical antibiotics for the treatment of impetigo? Key Message The evidence identified in this report supports the clinical efficacy of topical antibiotics, specifically mupirocin and fusidic acid, for the treatment of impetigo. Insufficient evidence was identified to support the clinical efficacy

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

8. Superficial Bacterial Skin Infections - Guidelines for Prescribing Topical Antibiotics for impetigo and folliculitis

Superficial Bacterial Skin Infections - Guidelines for Prescribing Topical Antibiotics for impetigo and folliculitis Superficial Bacterial Skin Infections - Guidelines for Prescribing Topical Antibiotics for impetigo and folliculitis - medSask Home - College of Pharmacy and Nutrition - University of Saskatchewan Toggle Menu Search the U of S Search Superficial Bacterial Skin Infections - Guidelines for Prescribing Topical Antibiotics for impetigo and folliculitis The skin has an effective (...) system of cells in the dermis and epidermis which helps prevent infection. Skin infections usually occur because bacteria enter through a cut or other disruption in the integrity of the skin Common skin infections include impetigo, folliculitis, furuncles (boils) and carbuncles Impetigo (see images at ) is the most common bacterial infection in children and is highly contagious by direct contact There are two types: non-bullous impetigo , which is the most common, most often occurs in children aged 2

2017 medSask

9. Impetigo

Impetigo Impetigo - NICE CKS Share Impetigo: Summary Impetigo is a common superficial bacterial infection of the skin. The two main clinical forms are non-bullous impetigo and bullous impetigo. Non-bullous impetigo is caused by Staphylococcus aureus , Streptococcus pyogenes or a combination of both and accounts for the majority of cases (about 70%). Bullous impetigo is caused by Staphylococcus aureus — bullae are fluid filled lesions which are usually more than 5mm in diameter. Impetigo caused (...) by Meticillin-resistant Staphylococcus aureus (MRSA) is becoming increasingly common. Impetigo affects all age groups but is most common in young children. The annual incidence is around 2.8% in children up to 4 years of age, and 1.6% in children 5–15 years of age. Impetigo is usually a mild infection, complications (such as glomerulonephritis and cellulitis) are rare. Non-bullous impetigo presents with thin walled vesicles or pustules (seldom seen on clinical examination as they rupture quickly) which

2018 NICE Clinical Knowledge Summaries

10. What is the best treatment for impetigo?

What is the best treatment for impetigo? What is the best treatment for impetigo? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics What is the best treatment for impetigo? View/ Open Date 2014-06 Format Metadata Abstract Q. What is the best treatment for impetigo? A. Although evidence is lacking to support a single best (...) treatment for impetigo, topical mupirocin, fusidic acid, gentamicin, and retapamulin are all at least 20% more likely than placebo to produce cure or improvement (strength of recommendation [SOR]: a meta-analysis of randomized controlled trials [RCTs] and a single RCT of retapamulin). Topical bacitracin and fusidicacid are 15% more likely than disinfectant solutions to cure or improve impetigo (SOR: a systematic review of RCTs). Oral antibiotics may be as effective as topical antibiotics (SOR: b, RCTs

2014 Clinical Inquiries

11. What is the best treatment for impetigo?

What is the best treatment for impetigo? What is the best treatment for impetigo? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics What is the best treatment for impetigo? View/ Open Date 2014-06 Format Metadata Abstract Q. What is the best treatment for impetigo? A. Although evidence is lacking to support a single best (...) treatment for impetigo, topical mupirocin, fusidic acid, gentamicin, and retapamulin are all at least 20% more likely than placebo to produce cure or improvement (strength of recommendation [SOR]: a meta-analysis of randomized controlled trials [RCTs] and a single RCT of retapamulin). Topical bacitracin and fusidicacid are 15% more likely than disinfectant solutions to cure or improve impetigo (SOR: a systematic review of RCTs). Oral antibiotics may be as effective as topical antibiotics (SOR: b, RCTs

2014 Clinical Inquiries

12. Efficacy of mass drug administration with ivermectin for control of scabies and impetigo, with coadministration of azithromycin: a single-arm community intervention trial. Full Text available with Trip Pro

Efficacy of mass drug administration with ivermectin for control of scabies and impetigo, with coadministration of azithromycin: a single-arm community intervention trial. In small community-based trials, mass drug administration of ivermectin has been shown to substantially decrease the prevalence of both scabies and secondary impetigo; however, their effect at large scale is untested. Additionally, combined mass administration of drugs for two or more neglected diseases has potential (...) practical advantages, but efficacy of potential combinations should be confirmed.The azithromycin ivermectin mass drug administration (AIM) trial was a prospective, single-arm, before-and-after, community intervention study to assess the efficacy of mass drug administration of ivermectin for scabies and impetigo, with coadministration of azithromycin for trachoma. Mass drug administration was offered to the entire population of Choiseul Province, Solomon Islands, and of this population we randomly

2019 Lancet infectious diseases

13. Prevalence of scabies and impetigo three years after mass drug administration with ivermectin and azithromycin. Full Text available with Trip Pro

Prevalence of scabies and impetigo three years after mass drug administration with ivermectin and azithromycin. Ivermectin-based mass drug administration has emerged as a promising strategy for the control of scabies and impetigo in settings where the diseases are endemic. Current follow-up data are limited to 12 months for the majority of studies. Longer term data are vital to inform the sustainability of interventions.We conducted a prevalence survey for scabies and impetigo in 10 villages (...) in Choiseul province of the Solomon Islands 36 months after a single round of ivermectin and azithromycin mass drug coadministration. In the primary analysis we compared the prevalence of scabies and impetigo at 36 months to the prevalence at baseline.At 36 months the prevalence of scabies was 4.7% (95% CI 3.6-6.1) which was significantly lower than at baseline (18.7%, relative reduction 74.9%, 95% CI 61.5 - 87.7%, p < 0.001). The prevalence of impetigo was 9.6% (95% CI 8.1-11.4%), significantly lower

2019 Clinical Infectious Diseases

14. Prevalence of scabies and impetigo in the Solomon Islands: a school survey. Full Text available with Trip Pro

Prevalence of scabies and impetigo in the Solomon Islands: a school survey. Scabies, a parasitic disease of the skin, is a major public health problem, largely affecting children. Scabies is often complicated by impetigo which can result in serious complications including invasive infections and immune mediated diseases. Scabies and impetigo are reported to have high prevalence in tropical settings including the Solomon Islands.We conducted a cross-sectional prevalence survey at Gizo Primary (...) School in the Western Province of the Solomon Islands in August 2018. The diagnosis of scabies was based on criteria developed by the International Alliance for the Control of Scabies in 2018. Population attributable risk was calculated to determine the effect of scabies on the prevalence of impetigo, and both adjusted and unadjusted risk ratios were calculated to identify differences between sexes and age groups.A total of 324 students were assessed (47.5% of those enrolled at the school

2019 BMC Infectious Diseases

15. Ozenoxacin Cream, 1% - Topical Treatment of Impetigo. (Abstract)

Ozenoxacin Cream, 1% - Topical Treatment of Impetigo. 28270312 2019 07 08 2019 07 08 1540-9740 15 1 2017 Skinmed Skinmed Ozenoxacin Cream, 1% - Topical Treatment of Impetigo. 57-59 Gupta Aditya K AK Department of Medicine, University of Toronto School of Medicine, Toronto, Ontario, Canada, Dallas, TX; agupta@execulink.com. Mediprobe Research Inc., London, Ontario, Canada, Dallas, TX. Versteeg Sarah G SG Mediprobe Research Inc., London, Ontario, Canada, Dallas, TX. Abramovits William W (...) therapeutic use Female Follow-Up Studies Humans Impetigo diagnosis drug therapy Male Ointments administration & dosage Quinolones therapeutic use Severity of Illness Index Treatment Outcome 2017 3 9 6 0 2017 3 9 6 0 2019 7 10 6 0 epublish 28270312

2019 Skinmed Controlled trial quality: uncertain

16. Topical Antibacterial Agent for Treatment of Adult and Pediatric Patients With Impetigo: Pooled Analysis of Phase 3 Clinical Trials. (Abstract)

Topical Antibacterial Agent for Treatment of Adult and Pediatric Patients With Impetigo: Pooled Analysis of Phase 3 Clinical Trials. Ozenoxacin is a novel topical antibacterial agent with potent bactericidal activity against Gram-positive bacteria that has been developed as a 1% cream for treatment of impetigo. This article presents pooled results of pivotal clinical trials of ozenoxacin with the objective of evaluating the efficacy, safety, and tolerability of ozenoxacin 1% cream after twice (...) -daily topical treatment for 5 days in patients with impetigo. A pooled analysis was performed of individual patient data from two multicenter, randomized, double-blind, vehicle-controlled phase 3 registration studies conducted in patients with impetigo. Both clinical trials followed a similar methodology. Patients were randomized 1:1 to ozenoxacin or vehicle. One trial included retapamulin as an internal control. Efficacy was measured using the Skin Infection Rating Scale and microbiological culture

2018 Journal of drugs in dermatology : JDD Controlled trial quality: uncertain

17. Scabies and impetigo in Timor-Leste: A school screening study in two districts Full Text available with Trip Pro

Scabies and impetigo in Timor-Leste: A school screening study in two districts Scabies and impetigo are common and important skin conditions which are often neglected in developing countries. Limited data have been published on the prevalence of scabies and impetigo in Timor-Leste. Sequelae including cellulitis, bacteraemia, nephritis, acute rheumatic fever and rheumatic heart disease contribute significantly to the burden of disease.School students were recruited from schools in Dili (urban (...) ) and Ermera (rural) in Timor-Leste for an epidemiological study in October 2016. A standard questionnaire was used to record demographics, anthropometry and skin examination results. Impetigo and scabies were diagnosed based on clinical examination of exposed surfaces, and clinical photographs were reviewed for correlation by an infectious diseases paediatrician. Prevalence of scabies and impetigo were calculated and binary risk factor associations were described using relative risks and 95% confidence

2018 PLoS neglected tropical diseases

18. Randomised trial of community treatment with azithromycin and ivermectin mass drug administration for control of scabies and impetigo. Full Text available with Trip Pro

Randomised trial of community treatment with azithromycin and ivermectin mass drug administration for control of scabies and impetigo. Scabies is a public health problem in many countries, with impetigo and its complications important consequences. Ivermectin based mass drug administration (MDA) reduces the prevalence of scabies and, to a lesser extent, impetigo. We studied the impact of co-administering azithromycin on the prevalence of impetigo and antimicrobial resistance.Six communities (...) were randomized to receive either ivermectin-based MDA or ivermectin-based MDA co-administered with azithromycin. We measured scabies and impetigo prevalence at baseline and 12 months. We collected impetigo lesions swabs at baseline, 3 and 12 months to detect antimicrobial resistance.At baseline, scabies and impetigo prevalences were 11.8% and 10.1% in the ivermectin-only arm and 9.2% and 12.1% in the combined treatment arm. At 12 months, the prevalences had fallen to 1.0% and 2.5

2018 Clinical Infectious Diseases Controlled trial quality: uncertain

19. Impetigo incidence and treatment: a retrospective study of Dutch routine primary care data. (Abstract)

Impetigo incidence and treatment: a retrospective study of Dutch routine primary care data. There is a lack of recently published data on impetigo presentation incidence and treatment practices in the routine Western European primary care setting.To investigate impetigo incidence, treatments and recurrence in primary care in the Netherlands.A retrospective, observational study. Electronic records of patients treated for impetigo in 2015 at 29 general practices in Utrecht and surrounds were (...) reviewed. An episode of impetigo was defined as one or more patient-doctor contacts within 8 weeks of the index consultation. Within an episode, patient demographics and prescribing patterns were analysed including number of treatments, and the category and sequence of individual medicines.A total of 1761 impetigo episodes were managed, with an incidence rate of 13.6 per 1000 person years. Impetigo peaked in summer. Most patients, the majority children, experienced a single episode (93%), and 25% had

2018 Family Practice

20. Impetigo Herpetiformis: Review of Pathogenesis, Complication, and Treatment Full Text available with Trip Pro

Impetigo Herpetiformis: Review of Pathogenesis, Complication, and Treatment Impetigo herpetiformis (IH) is among rare dermatosis of pregnancy, which is currently considered as a form of generalized pustular psoriasis. It is diagnosed by characteristic lesions of erythematous patches and grouped pustules mostly in the third trimester of pregnancy and may have systemic associations. A variety of complications have been reported in the course of IH. Treatment of IH can be quite challenging

2018 Dermatology research and practice

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>